Treatment Overview
Treatment for Myelodysplastic Syndromes (MDS) depends on several factors including your risk category, blood counts, symptoms, age, and overall health. Your healthcare team will work with you to develop a personalized treatment plan.
Lower-risk MDS typically focuses on managing symptoms and maintaining quality of life through supportive care. Higher-risk MDS may require more intensive treatments aimed at controlling the disease and preventing progression to acute leukemia.
Treatment decisions should be made in consultation with an MDS specialist who can explain all available options and help you weigh the benefits and risks.
Supportive Care
- Red blood cell transfusions
- Platelet transfusions
- Growth factors (EPO, G-CSF)
- Iron chelation therapy
Drug Therapies
- Azacitidine (Vidaza)
- Decitabine (Dacogen)
- Lenalidomide (Revlimid)
- Luspatercept (Reblozyl)
Bone Marrow Transplant
- Allogeneic stem cell transplant
- Donor matching required
- Best for younger patients
- Requires good overall health
Clinical Trials
- Novel therapies
- Combination treatments
- Close medical monitoring
- Contributing to research
Treatment Decision Factors
- Risk Category – Lower-risk vs higher-risk MDS determines treatment intensity
- Blood Counts – Degree of cytopenias affects supportive care needs
- Chromosomal Changes – Genetic abnormalities guide therapy selection
- Age & Health Status – Overall fitness determines eligibility for intensive treatments
- Symptoms – Impact on quality of life influences treatment goals
- Transfusion Needs – Dependence on transfusions may indicate need for disease-modifying therapy
Important Note
Treatment should be managed by a hematologist or oncologist with MDS expertise. Consider getting a second opinion, especially for higher-risk MDS or when considering transplant.
Discuss all options with your care team to understand which treatments align with your personal goals and values.
